Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eton Pharmaceuticals reports robust Q4 earnings, eyes accelerated growth

Eton Pharmaceuticals reported strong financial performance in Q4 2022, with a focus on accelerating growth, expanding product portfolio, and doubling sales and royalty revenue in 2023. The strategic transition to an in-house sales force for key products reflects proactive sales strategy control and market expansion efforts. While facing challenges in managing increased R&D expenses, Eton is well-positioned to capitalize on growth opportunities and achieve its long-term goal of commercializing rare disease products.

Eton Pharmaceuticals Reports Record Sales in Q1 2023, Eyes Growth

Eton Pharmaceuticals delivered impressive Q1 results with record sales and revenue growth, driven by successful product launches and strategic marketing initiatives. While facing challenges in managing expenses and legal matters, the company remains optimistic about its growth prospects and product development plans.

Eton Pharmaceuticals excels in Q2, eyes rare disease expansion

Eton Pharmaceuticals demonstrated strong financial performance and strategic growth initiatives in Q2 2023.
While facing regulatory challenges and timeline risks, the company's focus on rare diseases and acquisitions positions it for future growth.
With a solid cash position, successful product launches, and revenue projections, Eton is poised for continued success and value creation.
Navigating challenges and capitalizing on opportunities will be crucial for Eton to sustain its growth trajectory and maximize shareholder value.

Eton Pharmaceuticals excels in Q3, eyes rare disease market growth

Eton Pharmaceuticals demonstrated strong financial performance in Q3 2023, driven by revenue growth and operational efficiency.
While facing challenges in expense management and short-term profitability, the company remains focused on expanding its product portfolio and market presence.
With a solid cash position, strategic acquisitions, and a clear growth strategy, Eton is poised for continued success and revenue expansion in the coming quarters.

Eton Pharmaceuticals excels in Q4, eyes positive net income in 2024

Eton Pharmaceuticals delivered strong financial performance in Q4 2023, with revenue growth, positive cash flow, and a path to positive GAAP net income in 2024. The company's well-capitalized position, promising pipeline, and strategic growth initiatives position it for continued success. However, managing increasing operating expenses and ensuring the accretive nature of future acquisitions are key challenges.

Eton Pharmaceuticals reports robust Q1 revenue growth and strategic expansions

Eton Pharmaceuticals' Q1 performance reflects consistent revenue growth and strategic advancements.
While facing competition and M&A caution, the company is poised for growth with new products.
Opportunities lie in upcoming NDA approvals, product developments, and maintaining financial discipline.
Overall, Eton's prudent financial management and growth strategies position it for future success.

Eton Pharmaceuticals reports record Q3 earnings, eyes transformative acquisition

Eton Pharmaceuticals delivered strong financial performance in Q3 2024, with robust revenue growth, positive net income, and a strategic acquisition on the horizon. While facing challenges in sales force realignment and increased expenses, the company is poised to capitalize on opportunities with Increlex and ET-400.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DEER PARK, Ill., Feb.  19, 2020  (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today provided an update on its ET-105 product candidate, which is currently under review with the U.S. Food and Drug Administration (FDA).

Eton Pharmaceuticals Provides Update on ET-105 Program

Clovis Oncology

Immunomedics

Perrigo

vTv Therapeutics

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

DEER PARK, Ill., Jan.  21, 2020  (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, announced it has entered into a co-promotion agreement with Xellia Pharmaceuticals for the promotion of Biorphen® (phenylephrine HCl), the first and only FDA approved ready-to-use formulation of phenylephrine injection indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.  “We are excited to collaborate with Xellia on the promotion of Biorphen. Given our overlapping target markets, this agreement is a compelling opportunity for Eton to increase Biorphen’s commercial footprint and leverage Xellia’s established relationships with hospitals that have adopted ready-to-use injectable products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “We have been pleased with the customer reaction to Biorphen in our first few weeks since launch, and we look forward to working with Xellia to continue driving adoption of Biorphen”  “This is a great opportunity for us to work with Eton to co-promote Biorphen; the collaboration fits well with our overall mission to bring life-saving medicines that address unmet patients’ needs.  Eton has a similarly bold company culture and focus to Xellia, which aligns with our ambition to bring more ready-to-use products to the US market where time is critical to the patient and in alignment to industry guidelines” said Carl-Aake Carlsson, CEO of Xellia Pharmaceuticals.  Xellia’s hospital sales force will immediately begin promoting Biorphen in certain market segments in collaboration with Eton’s existing commercial team. The agreement significantly increases the number of sales representatives actively promoting Biorphen and provides Eton with immediate access to accounts that have already adopted Xellia’s Vanco Ready, a ready-to-use formulation of Vancomycin injection. In addition, Xellia will be expanding its sales force to support the co-promotion. Eton will continue to promote Biorphen to all market segments. Xellia will receive a commission on Biorphen sales realized from certain customer accounts.  About Biorphen Biorphen® (phenylephrine HCI) Injection is the first and only FDA-approved ready-to-use formulation of phenylephrine for treating clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Ready-to-use Biorphen can be standardized and stocked in operating rooms, emergency departments and intensive care units, as well as in crash carts throughout the hospital. With a three-year shelf life, Biorphen can be stocked throughout hospitals without frequent restocking. The market for ready-to-use phenylephrine injection is estimated to be more than 20 million doses annually.  Indications and Usage BIORPHEN injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.  Important Safety Information  Contraindications None.  Warnings and Precautions: BIORPHEN can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. Can also cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs. Extravasation during intravenous administration may cause necrosis or sloughing of tissue. Can cause severe bradycardia and decreased cardiac output, renal toxicity, augmented pressor effect in patients with autonomic dysfunction and pressor effect with concomitant oxytocic drugs.  Adverse Reactions  Most common adverse reactions during treatment: nausea, vomiting, and headache.  To report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals, Inc. at 1-888-450-0568 or FDA at 1-800-FDA-1088.  Drug Interactions Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids.

Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

A Small Bet On Eton Pharmaceuticals

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of   Phenylephrine ~

Eton Pharmaceuticals Announces Commercial Availability of Biorphen® (phenylephrine HCI) Injection

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q3 2019 Results - Earnings Call Transcript

DEER PARK, Ill., Nov.  13, 2019  (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility with SWK Holdings Corporation.

Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings

Eton Pharmaceuticals Inc. (NASDAQ: ETON) shares jumped on Tuesday after the firm announced that the U.S.

Eton Pharma Wins Big With FDA Hypotension Treatment Approval

~  Biorphen is the First and Only Ready-to-Use FDA-Approved Injectable Formulation of Phenylephrine ~

Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection

DEER PARK, Ill., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer, will participate in the Lake Street 3rd Annual Best Ideas Growth Conference on Thursday, September 12, 2019 in New York, NY.

Eton Pharmaceuticals to Participate in Lake Street 3rd Annual Best Ideas Growth Conference

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q2 2019 Results - Earnings Call Transcript

Even after the recent sell-off, shares have risen by 15% since IPO pricing.

Eton Pharmaceuticals: Short-Term Setback, Proven Business Model

Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.

Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall

Eton Pharmaceuticals (NASDAQ: ETON) shares are trading lower after the U.S Food and Drug Administration sent a Complete Response Letter to the company for EM-100.

Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter

Harrow Health holds large equity stakes in promising pre-clinical ophthalmology companies that aren't being factored into the current stock price.

Harrow Health, Inc. Is Quickly Taking Over The Ophthalmology Pharmaceutical Market

Eton Pharmaceuticals' (ETON) CEO Sean Brynjelsen on Q1 2019 Results - Earnings Conference Call

News for Eton Pharmaceuticals Inc Stock (ETON)